Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Chronic Graft-Versus-Host Disease
jRCT2011240011Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of axatilimab in chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Primary endpoint: Overall Response Rate in the First 6 Cycles. Started Jul 2024; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on jRCT2011240011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240011.